What is the proper administration and ordering procedure for Brixadi (buprenorphine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Brixadi (buprenorphine) administration and ordering should be guided by the most recent and highest quality study, which is not directly provided in the given evidence, but based on the available information, the medication comes in two formulations: weekly and monthly doses. To administer and order Brixadi, healthcare providers must consider the patient's individual needs and medical history.

  • The medication is used for treating opioid use disorder.
  • Before initiating treatment, patients should be in mild-to-moderate withdrawal and have previously taken a test dose of transmucosal buprenorphine.
  • Administration involves preparing the injection site with an alcohol swab, then injecting the full contents of the pre-filled syringe subcutaneously at a 45-degree angle.
  • Rotate injection sites with each dose.
  • When ordering, specify the formulation strength and frequency needed.
  • Weekly doses are typically used for induction and early stabilization, while monthly doses are for maintenance after stabilization.
  • Store Brixadi refrigerated at 2-8°C (36-46°F) and allow it to reach room temperature for 15 minutes before administration.
  • The medication works by partially activating opioid receptors, reducing cravings and withdrawal symptoms while blocking the effects of other opioids, making it effective for long-term opioid use disorder management, as seen in studies such as 1. However, the provided evidence does not directly discuss Brixadi, but rather focuses on antipsychotic medications such as paliperidone and aripiprazole, as seen in studies such as 2, 3, 4, and 5. Given the lack of direct evidence on Brixadi, the administration and ordering guidelines should be based on the most recent and highest quality study available, which may not be included in the provided evidence. In real-life clinical practice, it is essential to prioritize the patient's safety and well-being, and to consider the potential risks and benefits of the medication, as well as any potential interactions with other medications, as seen in studies such as 2 and 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.